Hologic (NSDQ:HOLX) posted fourth-quarter results today that handily beat the consensus forecast on Wall Street, concluding an impressive year of growth on the back of robust COVID-19 testing revenue.
The Marlborough, Massachusetts–based diagnostics and women’s health company reported quarterly profits of $328.8 million — or $1.28 per diluted share — on sales of nearly $1.32 billion for the three-month period ended Sept. 25, 2021.